glp 1 fgf21 agonist boehringer Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Gut hormone-based pharmacology: novel formulations
Description
95% CI, 1.19-1.47) vs
Circ Res
How Often
Co-authors include Jennifer Hwang, DO, Neda Laiteerapong, MD, Elbert Huang, MD and David D
Research Evidence Comparison# Orforglipron# The ATTAIN program includes ATTAIN-1 (obesity, 12.4% weight loss at 36 mg, 72 weeks, published in NEJM), ATTAIN-2 (obesity + T2D, 10.5% weight loss), and ATTAIN-MAINTAIN (weight maintenance after injectable switch)
